MARKET

HRTX

HRTX

Heron Therapeutics Inc
NASDAQ
0.8251
+0.0288
+3.62%
Closed 19:58 03/26 EDT
OPEN
0.7998
PREV CLOSE
0.7963
HIGH
0.8740
LOW
0.7800
VOLUME
7.33M
TURNOVER
0
52 WEEK HIGH
2.610
52 WEEK LOW
0.7510
MARKET CAP
155.56M
P/E (TTM)
-6.8134
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at HRTX last week (0316-0320)?
Weekly Report · 4d ago
Weekly Report: what happened at HRTX last week (0309-0313)?
Weekly Report · 03/16 09:38
Weekly Report: what happened at HRTX last week (0302-0306)?
Weekly Report · 03/09 09:40
Heron Therapeutics Signals Profitable Growth After Strong Quarter
TipRanks · 03/06 00:20
Weekly Report: what happened at HRTX last week (0223-0227)?
Weekly Report · 03/02 09:39
Heron (HRTX) Q4 2025 Earnings Call Transcript
NASDAQ · 02/26 21:26
Heron Therapeutics: Profitable Growth Outlook and Acute Care Momentum Underpin Buy Rating and $3 Target
TipRanks · 02/26 21:05
Heron Therapeutics outlines $173M–$183M 2026 sales targets amid acute care momentum and expanded commercial investment
Seeking Alpha · 02/26 20:09
More
About HRTX
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutics that improve medical care. Its acute care product portfolio includes ZYNRELEF, APONVIE, CINVANTI, and SUSTOL. ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low-dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is the intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist indicated for postoperative nausea and vomiting in adults. CINVANTI is an IV formulation of aprepitant, a substance NK1 receptor antagonist. SUSTOL is the first extended-release 5-HT3 receptor antagonist approved for the prevention of acute and delayed nausea and vomiting associated with both MEC and anthracycline and cyclophosphamide combination chemotherapy regimens.

Webull offers Heron Therapeutics Inc stock information, including NASDAQ: HRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HRTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HRTX stock methods without spending real money on the virtual paper trading platform.